An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of beloranib in obese subjects with hypothalamic injury.
Obesity|Over-weight|Hypothalamic Injury|Craniopharyngioma
DRUG: ZGN-440 sterile diluent|DRUG: ZGN-440 for injectable suspension
Change in body weight from baseline to the end of the randomized dosing period., 4 weeks
Change in lipid profile (cholesterol, LDL, HDL, triglycerides) from baseline to the end of the randomized dosing period, 4 weeks|Change in hs-CRP from baseline to the end of the randomized dosing period., 4 weeks|Change in hunger from baseline to the end of the randomized dosing period., 4 weeks|Change in quality of life from baseline to the end of the randomized dosing period., 4 weeks
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of beloranib in obese subjects with hypothalamic injury.